Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

KEYTRUDA 25 mg/mL concentrate for solution for infusion

Active Ingredient:
pembrolizumab
Company:  
Merck Sharp & Dohme (UK) Limited See contact details
ATC code: 
L01FF02
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Product Information HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Explanatory note on update to Risk Minimisation Materials

Short description of latest update of the Keytruda Materials
{pdf_link}

Patient Card for Keytruda

The risk minimisation materials for pembrolizumab were developed as a condition of the marketing authorisation grant for this product. The patient alert card should be issued to and carried by patients being treated with pembrolizumab and provides important safety information to minimise the risk of immune-related adverse reactions. In addition it contains emergency contact details for the patient and their specialist,

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Merck Sharp & Dohme (UK) Limited
Company image
Address
120 Moorgate, London, EC2M 6UR, UK
WWW
http://www.msd-uk.com/
Telephone
+44 (0)208 154 8000 (all hours)
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0)208 154 8001